Amyotrophic Lateral Sclerosis Treatment Market Regional Analysis

Amyotrophic Lateral Sclerosis Treatment Market size was valued at USD 704.02 Million in 2023 and is poised to grow from USD 748.37 Million in 2024 to USD 1220.08 Million by 2032, growing at a CAGR of 6.3% during the forecast period (2025-2032).

Global amyotrophic lateral sclerosis treatment market is slightly fragmented in nature due to the presence of several companies operating globally as well as regionally. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some companies are Mitsubishi Tanabe Pharma Corporation, Sun Pharmaceutical Industries Ltd., CORESTEM, Inc, BrainStorm Cell Limited, Amylyx Pharmaceuticals Inc., AB Science, Ionis Pharmaceuticals, Biohaven Pharmaceutical, Biogen, and F. Hoffmann-La Roche AG. 'Mitsubishi Tanabe Pharma Corporation', 'BrainStorm Therapeutics', 'Biogen Inc.', 'Sanofi S.A.', 'Genentech Inc.', 'Cytokinetics Inc.', 'Avanir Pharmaceuticals, Inc.', 'Novartis International AG', 'Ionis Pharmaceuticals, Inc.', 'Neuraltus Pharmaceuticals, Inc.', 'Pfizer Inc.', 'Anavex Life Sciences Corp.', 'AB Science', 'Biohaven Pharmaceutical Holding Company Ltd.', 'Ono Pharmaceutical Co., Ltd.', 'Bausch Health Companies Inc.', 'GW Pharmaceuticals plc', 'Mitsubishi Chemical Corporation', 'Regeneron Pharmaceuticals Inc.', 'Biocytogen, LLC.'

Amyotrophic lateral sclerosis treatment market is projected to be driven by a rise in prevalence of amyotrophic lateral sclerosis disease. According to the Centers for Diseases Control and Prevention (CDC), in 2016, between 14,500 and 15,000 people in the U.S. had amyotrophic lateral sclerosis, of these about 5,000 people are diagnosed annually. Globally, about 2 – 5 people in every 100,000 are affected by ALS. Additionally, inclination toward sedentary lifestyle and increase in the geriatric population fuel the demand for targeted and symptomatic treatment options. This is expected to drive the amyotrophic lateral sclerosis treatment industry during the forecast period.

Due to the hectic schedule of the individual and changing lifestyle there is rising incidences of neurodegenerative disorders which is driving the amyotrophic lateral sclerosis treatment market. Beside this, expanding geriatric population, who are more susceptible to such neurological ailments, is also augmenting the amyotrophic lateral sclerosis treatment market growth. Furthermore, several NGO and private organizations are undertaking numerous initiatives to increase awareness regarding the diagnosis and treatment of ALS among the masses. This, in turn, is creating a positive outlook for the market. Additionally, the growing penetration of targeted symptomatic treatment options for ALS is acting as a significant growth-inducing factor.

North America had the largest amyotrophic lateral sclerosis treatment market share in 2023 and is expected to maintain that position throughout the forecast period. The factors driving the market are high healthcare expenditure, favorable reimbursement policies, high demand for ALS drugs, and established healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, approximately 16,583 cases of amyotrophic lateral sclerosis were identified in the United States in 2015.